Evidence map›Paper›PMID 27228348›Full record

ArticleScientific reports2016

Drug vaping applied to cannabis: Is "Cannavaping" a therapeutic alternative to marijuana?

Vincent Varlet, Nicolas Concha-Lozano, Aurélie Berthet, Grégory Plateel, Bernard Favrat, Mariangela De Cesare, Estelle Lauer, Marc Augsburger, Aurélien Thomas, Christian Giroud

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cannabis concentrate vaping chemistry.Frontiers in toxicology · 2025
    Review
  6. Article
  7. Article
  8. ΔCannabis and cannabinoid research · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Carbonyl Compounds in Mainstream Smoke of Hemp Cigarettes.Cannabis and cannabinoid research · 2021
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Vincent VarletForensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Geneva-Lausanne, Switzerland.
Nicolas Concha-LozanoInstitute for Work and Health (IST), University of Lausanne, University of Geneva, Lausanne, Switzerland.
Aurélie BerthetInstitute for Work and Health (IST), University of Lausanne, University of Geneva, Lausanne, Switzerland.
Grégory PlateelInstitute for Work and Health (IST), University of Lausanne, University of Geneva, Lausanne, Switzerland.
Bernard FavratPsychology and Traffic Medicine Unit, University Centre of Legal Medicine, Lausanne, Switzerland.
Mariangela De CesarePsychology and Traffic Medicine Unit, University Centre of Legal Medicine, Lausanne, Switzerland.
Estelle LauerForensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Geneva-Lausanne, Switzerland.
Marc AugsburgerForensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Geneva-Lausanne, Switzerland.
Aurélien ThomasForensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Geneva-Lausanne, Switzerland.
Christian GiroudForensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Geneva-Lausanne, Switzerland.
University Centre of Legal Medicine · CHUniversity of Geneva · CHInstitute for Work and Health · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic cannabis administration is increasingly used in Western countries due to its positive role in several pathologies. Dronabinol or tetrahydrocannabinol (THC) pills, ethanolic cannabis tinctures, oromucosal sprays or table vaporizing devices are available but other cannabinoids forms can be used. Inspired by the illegal practice of dabbing of butane hashish oil (BHO), cannabinoids from cannabis were extracted with butane gas, and the resulting concentrate (BHO) was atomized with specific vaporizing devices. The efficiency of "cannavaping," defined as the "vaping" of liquid refills for e-cigarettes enriched with cannabinoids, including BHO, was studied as an alternative route of administration for therapeutic cannabinoids. The results showed that illegal cannavaping would be subjected to marginal development due to the poor solubility of BHO in commercial liquid refills (especially those with high glycerin content). This prevents the manufacture of liquid refills with high BHO concentrations adopted by most recreational users of cannabis to feel the psychoactive effects more rapidly and extensively. Conversely, "therapeutic cannavaping" could be an efficient route for cannabinoids administration because less concentrated cannabinoids-enriched liquid refills are required. However, the electronic device marketed for therapeutic cannavaping should be carefully designed to minimize potential overheating and contaminant generation.

Indexed as

Marijuana SmokingButanesCannabinoidsCannabisDronabinolElectronic Nicotine Delivery SystemsFeasibility StudiesHumansMedical MarijuanaReproducibility of ResultsVapingbutaneButanesCannabinoidsDronabinolHashish oilMedical Marijuana

Identifiers

PMID27228348
PMCPMC4881394
OpenAlexW2406252675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.